Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead product candidate, PALI-2108, is being developed for inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD). The company operates as a single segment and has no product revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2,868) | $(3,487) | $(7,882) | $(11,094) |
| Net Loss Per Share (Basic & Diluted) | $(0.38) | $(2.32) | $(1.38) | $(9.50) |
| Total Operating Expenses | $2,922 | $3,593 | $8,075 | $11,477 |
| Cash and Cash Equivalents (Sept 30, 2025) | $5,227 | |||
| Restricted Cash (Sept 30, 2025) | $26 | |||
| Total Liabilities (Sept 30, 2025) | $3,761 | |||
| Stockholders' Equity (Sept 30, 2025) | $3,212 |
Operating Expenses Breakdown (9M 2025): Research and Development ($4,019); General and Administrative ($4,056).
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 19% in Q3 2025 and 30% in the nine months ended September 30, 2025, compared to the prior year periods. This was primarily driven by a significant reduction in preclinical joint development expenses related to the Giiant Pharma collaboration, as the Company assumed full responsibility for development costs after achieving "Proof of Concept" in October 2024.
- Net Loss Improvement: Net loss decreased by 18% in Q3 and 29% in the nine-month period year-over-year, reflecting the reduction in operating expenses.
- Cash Position: Cash and cash equivalents declined from $9.8 million at December 31, 2024, to $5.2 million at September 30, 2025, due to net cash used in operating activities of $7.7 million for the nine-month period.
- Equity Activity: Significant equity activity occurred in Q3 2025, including a warrant inducement transaction that resulted in the issuance of 4.3 million shares of common stock and 8.6 million replacement warrants.
Guidance, Outlook, and Material Events
- Subsequent Equity Offering: On October 2, 2025, the Company closed an underwritten public offering for gross proceeds of approximately $138 million. This transaction significantly improved liquidity and resolved substantial doubt about the Company's ability to continue as a going concern. Management expects these funds to support operations through Phase 2 primary efficacy readouts for UC (H2 2027) and FSCD (H1 2028).
- Clinical Progress: The Company completed dosing in its Phase 1 clinical study of PALI-2108 in healthy volunteers and UC patients, reporting positive safety and tolerability results. On October 16, 2025, the Company dosed the first patients in an exploratory Phase 1b cohort for FSCD.
- Warrant Inducement: In July 2025, the Company executed a warrant inducement agreement, reducing the exercise price of existing warrants and issuing replacement warrants. This generated approximately $3.9 million in gross proceeds but incurred significant non-cash equity issuance costs ($8.6 million).
- Internal Controls: The Company disclosed a material weakness in internal control over financial reporting related to the financial closing process and segregation of duties. Remediation efforts are ongoing, but the weakness remains as of September 30, 2025.
- Reverse Stock Split: Stockholders approved a proposal on October 17, 2025, authorizing the Board to effect a reverse stock split (ratio between 1-for-5 and 1-for-50) by December 31, 2025, to maintain Nasdaq listing compliance.
Investor Verification Checklist
- Liquidity Runway: Verify the net proceeds from the October 2025 offering and confirm the updated cash runway against the projected burn rate for Phase 2 trials.
- Going Concern Status: Confirm that the $138 million offering has formally removed the "substantial doubt" regarding the Company's ability to continue as a going concern.
- Internal Control Remediation: Monitor the progress of remediation efforts for the material weakness in internal controls over financial reporting to assess the reliability of future financial statements.
- Regulatory Acceptance: Assess the risk that the FDA may not accept data from the Canadian Phase 1 trials, potentially requiring additional U.S.-based trials.
- Dilution Impact: Evaluate the dilutive effect of the October 2025 offering (113 million shares + 84 million pre-funded warrants) and the outstanding 8.6 million replacement warrants from the July 2025 inducement.
- Milestone Obligations: Verify the status of the $235,000 milestone payment to Giiant Pharma triggered by the October 16, 2025, dosing of the first FSCD patient.